Active Filter(s):
Details:
Upon termination of the Agreement, all domestic and foreign rights with respect to guaranteed Mesenchymal Stem Cell 1 (gMSC®1), a regenerative cellular medicine for chondrogenesis in the knee, granted to Chugai from TWOCELLS will be returned to TWOCELLS.
Lead Product(s): gMSC1
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: gMSC1
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination April 13, 2023